racemic-CPSI-1306-DataSheet-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemE()-CPSI-1306Cat. No.: HY-110095CAS No.: 1309793-47-2分式: CHFNO分量: 310.3作靶點(diǎn): Others作通路: Others儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 6 mg/mL (19.34 mM; Need ultrasonic)Mass Solvent1

2、mg 5 mg 10 mg Concentration制備儲備液1 mM 3.2227 mL 16.1134 mL 32.2269 mL5 mM 0.6445 mL 3.2227 mL 6.4454 mL10 mM 0.3223 mL 1.6113 mL 3.2227 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。體內(nèi)實(shí)驗(yàn) 請根據(jù)您的實(shí)驗(yàn)動物和給藥式選擇適當(dāng)?shù)娜芙獍?，配制前請先配制澄清的儲備液，再依次添加助溶?為保證實(shí)驗(yàn)結(jié)果的可靠性，體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終

3、溶液中的體積占)：1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 0.6 mg/mL (1.93 mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 0.6 mg/mL (1.93 mM); Clear solution3. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 0.6 mg/mL (1.93 mM); Clear solution1/2 Master

4、 of Small Molecules 您邊的抑制劑師www.MedChemEBIOLOGICAL ACTIVITY物活性 ()-CPSI-1306具有服活性的、巨噬細(xì)胞游因 (MIF) 的拮抗劑。IC50 & Target MIF 1.體內(nèi)研究 Mice treated with CPSI-1306 show a significant drop in their blood glucose levels, which is associated with areduction in serum levels of inflammatory cytokines. As expected, c

5、ontrol mice treated with vehicle developNIDDM as characterized by high serum levels of glucose and inflammatory cytokine. Furthermore, they alsoshow that orally bioavailable CPSI-1306 can be effective in treating this disease 1. CPSI-1306-inducedkeratinocyte apoptosis could be appreciated as early a

6、s 30 minutes after a single UVB exposure. At 6, 24,and 48 hours following UVB exposure, the CPSI-1306-treated mice show significantly increased expressionof cleaved caspase-3 compared with the vehicle-treated mice. CPSI-1306 reduces acute UVB-inducedkeratinocyte DNA damage and UVB-induced acute infl

7、ammation 2.PROTOCOLAnimal Mice 1Administration 1 Six- to 8-wk-old female BALB/c mice and ICR mice are used in the study. Age- and sex-matched ICR miceare deprived of food for 20 h and then injected intraperitoneally with STZ (90 mg/kg). Beginning at 6 h afterSTZ injection, mice are administered CPSI

8、-1306 (1 or 0.1 mg/kg) or PBS daily in a single oral dose for 30 d1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Sanchez-Zamora Y, et al. Macrophage migration inhibitory factor is a therapeutic target in treatment of non-insulin-dependent diabetesmellitus. FASEB J. 2010 Jul;24(7):2583-90.2. Nagarajan P, et al. MIF antagonist (CPSI-1306) protects against UVB-induced squamous cell carcinoma. Mol Cancer Res. 2014Sep;12(9):1292-302.McePdfHeightCaution: Product has not been fully validated for medical ap